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Although many factors have been cited as the cause of acne, it has become
apparent that hormonal inIfuences play a major role in its development. Hamil-
ton (1) presented convincing evidence that testosterone propionate would pro-
duce acne in susceptible individuals and pointed out the absence of acne in
eunuchs. It has been found, too, that the administration of ACTH and corti-
sone, both of which have androgenic qualities, is followed in some cases by the
development of acne (2). While a preponderance of androgenic hormones is
often followed by acneform eruptions, it cannot be stated categorically that
such excesses in themselves account for the disturbance because there is a con-
comitant alteration of the estrogen—androgen ratio. In a number of patients
suffering from acne, it was found (3) that there was a moderate increase in the
urinary excretion of androgen and a moderate decrease in the urinary excretion
of estrogen which resulted in altered ratio. On the other hand, Lawrence and
Werthessen (4) noted a decrease in urinary estrogen with no significant change
in the excretion of urinary androgen, but they felt that the resulting increased
ratio of androgen to estrogen was the responsible inciting factor. The occurrence
of premenstrual exacerbation of acne is well known and has been ascribed to
the fact that at this period during the menstrual cycle, estrogen levels are at
their lowest and, as a result, the androgen—estrogen ratio is elevated (5—7).
In an effort to restore the endocrine balance, estrogens have been adminis-
tered to patients suffering from acne, with varying results. Sulzberger (2), re-
porting on the therapeutic effect of female sex hormones in refractory cases of
acne, stated that in one-third of these patients such hormones were a valuable
adjuvant, but untoward reactions occurred in a large number of cases. Nausea,
delayed menses, prolonged flow and "spotting" were often so severe that it
became necessary to stop the treatment. In a small series of cases, others reported
good (8, 9) and bad (10, 11) results following estrogen therapy.
A new synthetic estrogen, TACE, has been given therapeutic trial in a number
of patients suffering from acne. TACE differs from other commonly used estrogens
in several respects. After oral administration it is stored in the body fat from
which it is released slowly over a period of time (12, 13). In experimental ani-
mals, the administration of other estrogens has been shown to produce hyper-
plasia of the adrenals, but following TACE this effect is minimal (13, 14). This is
of some importance in the treatment of acne, a condition in which a relative ex-
cess of androgenic steroids is considered to be an important causal factor. In ad-
dition, the use of TACE is reported to produce very few undesirable side effects
(15).
* TACE (chlorotrianisene(tri-p-anisylohloroethylene)) kindly furnished by The William
S. Merrell Co.
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Forty patients were given the drug (see Table I). All of these cases were
young females except for three males. Nearly all were given 12 mgs. per day.
Since there may be storage in fat with gradual release, a few of the patients
were given the remedy throughout the cycle as well as just during the post-
ovulatory phase. The chart shows the effects of its administration. Many of
these patients were given topical applications simultaneously, and some of them
had x-ray therapy.
Flare Pre-
menstru-
ally, 20
Discontinued due to marked irregu-
larity of menses
Discontinued due to dysmenorrhea,
3 cases
Had to have D and C, 1 case
Increased sexual activity and spotting
between periods in 1 case
Missed two periods, 2 cases
Given to three males who were unim-
proved
Certainly this is not a cure for acne. Lynch (11) has demonstrated that many
with acne improve with no therapy. Of course, there are many factors involved.
Concommitant therapy, the age group observed, and even the temperature and
humidity are factors. Even with adequate controls, it is difficult to appraise
such a therapeutic agent in this disease. Many patients seemed to improve while
under observation.
The effect on the menses was less when the drug was given during the post-
ovulatory phase of the menstrual cycle than through the entire cycle. Then,
too, this effect seemed less after the drug had been taken for several months
than for the first few months. These young females seem to adapt to the added
estrogen. Perhaps the dose was too large. Maybe smaller doses would have had
as good or better effect on their acne with less effect on the menstrual cycle.
Several girls who developed tender breasts while on other estrogens did not do
so on TACE. Reactions certainly were no higher on this estrogen than on previ-
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ously tried chemicals; as a matter of fact, they were somewhat less, but still
occur. The three males taking the drug showed no improvement.
The exact approach to acne is still to be found. It appears likely that more
than one factor is at work (16).
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